Featured Research

from universities, journals, and other organizations

Are Older Patients Denied Access To Psychological Services Due To Ageism In The UK?

Date:
April 23, 2009
Source:
Cambridge University Press
Summary:
New research has found that there are serious gaps in the treatments available to older patients experiencing later life problems associated with old age including depression, anxiety disorders, panic disorder and sleep disorders in the United Kingdom.

New research conducted by Dr. Philip Wilkinson (Department of Psychiatry, University of Oxford, Warneford Hospital Headington, Oxford) for a review published in the Cognitive Behaviour Therapist (Cambridge University Press on behalf of the British Association for Behavioural and Cognitive Psychotherapies) has found that there are serious gaps in the treatments available to older patients experiencing later life problems associated with old age including depression, anxiety disorders, panic disorder and sleep disorders.

Dr. Philip Wilkinson states that despite a robust evidence base in support of the use of Cognitive Behavioural Therapy (CBT) in the treatment of mental disorders in younger adults, "trials with older people have generally been of poor methodological quality. Therefore, the potential of CBT to improve the outcome of late-life mental illness has not yet been adequately tested and demonstrated". There is, the author suggests, a strong case for retaining separate services for older people as their clinical needs may differ from younger adults.

Accessibility of services is another key issue that the article raises, although "CBT is one of the psychological therapies most frequently offered in the National Health Service, provision [to older patients] is patchy and relies on the availability of clinical psychologists". Moreover, "older adults have been severely under-represented" in GP referrals, hinting not only at a staff shortage of skilled clinical psychologists in the NHS but, even more worryingly, indicating an ageist bias in favour of younger cases on the part of GPs and clinical practitioners alike.

In a society that is rapidly getting older as a consequence of higher life expectancy brought about by medical advances and higher standards of living, this is indeed a major concern.

Dr. Wilkinson concludes that many of the randomized trials that served to give CBT the prominence it holds today apparently excluded older adults on the basis of age rather than more prognostic factors, such as the presence of dementia. "This reflects a failure to recognise that psychological treatments can indeed be relevant to older people and the problems they face. Data from trials that did include some older people indicate that age in itself does not affect outcome".

Despite recent increases in the range of CBT applications for older people, there appears to still be some prejudice in referring patients to these services and in inclusion of these patients in randomized clinical trials. Older people often have a preference for psychological treatments and presenting treatments as education rather than therapy can also increase their appeal.

According to Dr. Wilkinson, the lack of adequate CBT trials with older adults must be addressed, methodological limitations rectified, sample sizes increased to attain statistical validity, and the likelihood of bias minimized in order to tailor therapy to the particular problems of individuals, in this case older patient groups. For this reason, Dr. Wilkinson suggests developing standardized, reproducible CBT interventions and for these to be evaluated in large trials alongside medication or as part of case-management interventions.

Press coverage tends to highlight the problem of poor access to psychological treatments for older people; this review makes the case that development and evaluation of treatments are important too.


Story Source:

The above story is based on materials provided by Cambridge University Press. Note: Materials may be edited for content and length.


Cite This Page:

Cambridge University Press. "Are Older Patients Denied Access To Psychological Services Due To Ageism In The UK?." ScienceDaily. ScienceDaily, 23 April 2009. <www.sciencedaily.com/releases/2009/04/090423082917.htm>.
Cambridge University Press. (2009, April 23). Are Older Patients Denied Access To Psychological Services Due To Ageism In The UK?. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/04/090423082917.htm
Cambridge University Press. "Are Older Patients Denied Access To Psychological Services Due To Ageism In The UK?." ScienceDaily. www.sciencedaily.com/releases/2009/04/090423082917.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins